Meeting
2020 Gastrointestinal Cancers Symposium
The treatment strategy of the second-line chemotherapy for metastatic colorectal cancer (mCRC) patients (pts) with early progression in the first-line chemotherapy with bevacizumab (BEV), BEV beyond progression (BBP), or non-BBP.
Authors
Takeshi Kawakami
Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
Takeshi Kawakami , Shun Yamamoto , Seiichiro Mitani , Taito Esaki , Yasushi Tsuji , Naoki Izawa , Kentaro Kawakami , Yoshiyuki Yamamoto , Akitaka Makiyama , Kentaro Yamazaki , Toshiki Masuishi , Takako Eguchi Nakajima , Hiroyuki Okuda , Toshikazu Moriwaki , Narikazu Boku
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 113)
Abstract #
113
Poster Bd #
E21
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Quattro-II study: A multicenter randomized phase II study comparing capoxiri plus bevacizumab with FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer as the first-line treatment.
First Author: Akihito Tsuji
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 ASCO Annual Meeting
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz